Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:24:57 EDT Fri 17 Jul 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:PCVX - VAXCYTE INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PCVX - Q0.255.36·57.180.256.20+0.160.31,128.062,87412,98355.60  57.86  54.5964.785  29.09516:04:50Jul 0815 min RT 2¢

Recent Trades - Last 10 of 12983
Time ETExPriceChangeVolume
16:04:50Q56.200.161
16:04:40Q56.200.161
16:04:34Q56.200.161
16:04:27Q56.200.161
16:04:22Q56.200.161
16:04:03Q56.200.161
16:00:46Q56.200.16460
16:00:42Q56.200.16602
16:00:39Q56.200.163,720
16:00:39Q56.200.161,406

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-08 16:05U:PCVXNews ReleaseVaxcyte to Participate in Upcoming Investor Conferences
2026-06-02 16:05U:PCVXNews ReleaseVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
2026-05-06 16:05U:PCVXNews ReleaseVaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-07 16:05U:PCVXNews ReleaseVaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-03-23 08:30U:PCVXNews ReleaseVaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
2026-03-18 19:34U:PCVXNews ReleasePositive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
2026-02-24 16:05U:PCVXNews ReleaseVaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-11 16:05U:PCVXNews ReleaseVaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
2026-02-10 16:05U:PCVXNews ReleaseVaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
2026-02-05 16:05U:PCVXNews ReleaseVaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
2026-02-02 16:05U:PCVXNews ReleaseVaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2026-01-29 23:33U:PCVXNews ReleaseVaxcyte Announces Pricing of $550 Million Public Offering
2026-01-29 16:07U:PCVXNews ReleaseVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-01-22 17:00U:PCVXNews ReleaseVaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
2025-12-08 07:00U:PCVXNews ReleaseVaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
2025-11-04 16:05U:PCVXNews ReleaseVaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
2025-09-30 08:30U:PCVXNews ReleaseVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
2025-09-03 07:30U:PCVXNews ReleaseVaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
2025-08-06 16:05U:PCVXNews ReleaseVaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)